Zymeworks (NASDAQ:ZYME) Stock Price Expected to Rise, Truist Financial Analyst Says

Key Points

• Truist raised its price target on Zymeworks to $36 from $35 and maintained a Buy rating, implying 14.89% upside from the stock’s cited price of $31.34.
• Analyst sentiment is broadly positive: 12 analysts rate the stock Buy, one Hold, and one Sell; the consensus is Moderate Buy with an average target of $41.83.
• Zymeworks reported quarterly EPS of $2.28 and revenue of $512.92 million, exceeding the cited consensus estimates. A $250 million milestone payment from Jazz Pharmaceuticals contributed to the results, which may limit how much of the profit reflects recurring operations.

Zymeworks (NASDAQ:ZYME - Get Free Report) had its price objective upped by equities research analysts at Truist Financial from $35.00 to $36.00 in a report released on Tuesday, Benzinga reports. The firm currently has a "buy" rating on the stock. Truist Financial's price target would suggest a potential upside of 14.89% from the company's current price.

A number of other brokerages have also commented on ZYME. Jefferies Financial Group reissued a "buy" rating and issued a $52.00 price objective on shares of Zymeworks in a research report on Friday, October 23rd. Deutsche Bank Aktiengesellschaft set a $32.00 price objective on Zymeworks in a research report on Wednesday, August 26th. Weiss Ratings restated a "sell (d-)" rating on shares of Zymeworks in a research report on Thursday, October 15th. Citigroup reaffirmed a "market outperform" rating on shares of Zymeworks in a report on Monday, October 26th. Finally, Stifel Nicolaus set a $46.00 price target on shares of Zymeworks in a report on Friday, August 7th. Twelve analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $41.83.

Zymeworks Stock Performance

Zymeworks stock traded up $0.53 during trading hours on Tuesday, reaching $31.34. 416,053 shares of the company's stock traded hands, compared to its average volume of 777,676. Zymeworks has a fifty-two week low of $18.20 and a fifty-two week high of $31.97. The firm's 50 day moving average is $27.46 and its 200-day moving average is $25.38. The firm has a market capitalization of $2.21 billion, a price-to-earnings ratio of -15.48 and a beta of 1.32.

Zymeworks (NASDAQ:ZYME - Get Free Report) last released its quarterly earnings data on Monday, November 9th. The company reported $2.28 EPS for the quarter, beating analysts' consensus estimates of $2.27 by $0.01. Zymeworks had a negative return on equity of 72.30% and a negative net margin of 405.31%. The business had revenue of $512.92 million during the quarter, compared to the consensus estimate of $227.40 million. During the same quarter in the prior year, the company posted ($0.26) earnings per share. The firm's revenue was up 828.7% on a year-over-year basis. Analysts predict that Zymeworks will post 1.32 EPS for the current year.

Insider Activity

In other news, EVP Adam Schayowitz sold 13,832 shares of the firm's stock in a transaction that occurred on Friday, October 9th. The shares were sold at an average price of $25.85, for a total value of $357,557.20. Following the completion of the transaction, the executive vice president directly owned 23,205 shares in the company, valued at approximately $599,849.25. This trade represents a 37.35% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 37.73% of the stock is currently owned by corporate insiders.

Institutional Trading of Zymeworks

A number of hedge funds have recently made changes to their positions in ZYME. Deutsche Bank AG purchased a new position in shares of Zymeworks in the second quarter valued at about $10,383,000. Bank of America Corp DE purchased a new position in shares of Zymeworks in the 2nd quarter worth about $5,727,000. Rubric Capital Management LP raised its holdings in Zymeworks by 21.7% in the 1st quarter. Rubric Capital Management LP now owns 7,000,000 shares of the company's stock worth $175,280,000 after acquiring an additional 1,250,000 shares during the last quarter. Legal & General Group Plc bought a new position in shares of Zymeworks during the second quarter valued at $1,128,000. Finally, Jupiter Topco LLC purchased a new stake in Zymeworks in the second quarter worth approximately $476,000. 92.89% of the stock is owned by institutional investors.

More Zymeworks News

Here are the key news stories impacting Zymeworks this week:

• Positive Sentiment: HC Wainwright raised its price target to $56 from $55 and maintained a Buy rating, signaling substantial potential upside in the analyst’s view. Tickerreport article
• Positive Sentiment: Zymeworks raised its 2026 earnings guidance, a favorable update for the company’s near-term outlook. 2026 earnings guidance article
• Neutral Sentiment: Q3 results showed a sharp swing to profit, with EPS of $2.28 versus a loss a year earlier. Revenue was reported above estimates. A $250 million milestone payment from Jazz Pharmaceuticals contributed to the profit, so investors may view some of the results as nonrecurring. Milestone and earnings article
• Negative Sentiment: EPS beat one cited consensus estimate of $2.27 by a penny, but missed the Zacks estimate of $2.40, leaving the earnings comparison mixed. Zacks earnings article

Zymeworks Company Profile

Zymeworks Inc is a biotechnology company headquartered in Vancouver, Canada, that develops engineered medicines, with a focus on treatments for cancer and other serious diseases. Its antibody-engineering technologies are designed to create therapies that can engage multiple biological targets or modify immune responses.

The company's lead program is zanidatamab, a HER2-targeted bispecific antibody. In the United States, it is marketed by partner Jazz Pharmaceuticals as Ziihera for certain adults with previously treated, unresectable or metastatic biliary tract cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.